Advanced Breast Cancer Clinical Trials

251 clinical trials for Advanced Breast Cancer across international registries, including 65 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC — RECRUITING · PHASE2
• Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study — RECRUITING · PHASE2
• Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors — RECRUITING · PHASE1
• A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer — RECRUITING · PHASE1
• Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer — RECRUITING · PHASE2
• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors — RECRUITING · PHASE1
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer — RECRUITING · PHASE3
• Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment — RECRUITING · PHASE3
• A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer — RECRUITING · PHASE1
• Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer — RECRUITING · PHASE3
• Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype — RECRUITING · PHASE2
• A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer — RECRUITING · PHASE2
• A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• Timing of ctDNA Testing in Advanced Breast Cancer — RECRUITING
• Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors — RECRUITING · PHASE1
• Decision Support Tool for Patients With Advanced Breast Cancer — RECRUITING · NA
• Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer — RECRUITING · PHASE2
• Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer — RECRUITING · PHASE4
• A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors — RECRUITING · PHASE1
• Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors — RECRUITING · PHASE1
• A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer — RECRUITING · PHASE2
• A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer — RECRUITING
• RC48-ADC in HER2-low Advanced Breast Cancer — RECRUITING · NA
• A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer — RECRUITING · PHASE2
• Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer — RECRUITING · PHASE2
• Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. — RECRUITING · PHASE3
• MATRIX-IPC 2022-029 A phase I/II study evaluating Tuvusertib (M1774), an ATR Inhibitor, in combination with fulvestrant in hormone receptors-positive and HER2-negative, advanced breast cancers, resistant to CDK4/6 inhibitor plus aromatase inhibitor-based endocrine treatment and with homologous recombination deficiency, oncogenic driver activation and/or other molecular alterations associated with replication stress (RS) — RECRUITING · PHASE2
• Engage Psychosocial Intervention for Cancer Symptoms — RECRUITING · NA
• Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients — RECRUITING · NA
• Dalpiciclib in HR+/HER2- ABC — RECRUITING
• Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC — RECRUITING · PHASE2
• Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor — RECRUITING · PHASE2
• Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer — RECRUITING · PHASE2
• Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer — RECRUITING · PHASE2
• A Study of GC101 TIL in Advanced Breast Cancer (10hospital) — RECRUITING · PHASE1
• Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers — RECRUITING · PHASE2
• Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer — RECRUITING · PHASE2
• Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer — RECRUITING · PHASE2
• Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer — RECRUITING · PHASE2
• Trastuzumab Deruxtecan in Advanced Breast Cancer — RECRUITING
• A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors — RECRUITING · PHASE2
• The COMPASSION Study — RECRUITING · NA
• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer — RECRUITING · PHASE1
• Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer — RECRUITING · NA
• Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer — RECRUITING · NA
• Study of DM5167 in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• HS-10502 Combination Treatment in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor — RECRUITING · PHASE2
• Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency — RECRUITING · PHASE2

Refine this search